Edesa Biotech EDSA Stock
Edesa Biotech Price Chart
Edesa Biotech EDSA Financial and Trading Overview
Edesa Biotech stock price | 2.31 USD |
Previous Close | 0.86 USD |
Open | 0.87 USD |
Bid | 0 USD x 4000 |
Ask | 0 USD x 1800 |
Day's Range | 0.84 - 0.87 USD |
52 Week Range | 0.76 - 2.81 USD |
Volume | 9.55K USD |
Avg. Volume | 73.97K USD |
Market Cap | 17.69M USD |
Beta (5Y Monthly) | 0.805612 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.87 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.67 USD |
EDSA Valuation Measures
Enterprise Value | 10.36M USD |
Trailing P/E | N/A |
Forward P/E | -0.47214285 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.9138085 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -0.778 |
Trading Information
Edesa Biotech Stock Price History
Beta (5Y Monthly) | 0.805612 |
52-Week Change | -46.91% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.81 USD |
52 Week Low | 0.76 USD |
50-Day Moving Average | 0.97 USD |
200-Day Moving Average | 1.24 USD |
EDSA Share Statistics
Avg. Volume (3 month) | 73.97K USD |
Avg. Daily Volume (10-Days) | 62.24K USD |
Shares Outstanding | 20.59M |
Float | 13.69M |
Short Ratio | 9.44 |
% Held by Insiders | 19.21% |
% Held by Institutions | 16.29% |
Shares Short | 631.78K |
Short % of Float | 3.78% |
Short % of Shares Outstanding | 3.07% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | September 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | September 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -53.98% |
Return on Equity (ttm) | -101.98% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -13319690 USD |
Net Income Avi to Common (ttm) | -13270097 USD |
Diluted EPS (ttm) | -0.63 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 7.47M USD |
Total Cash Per Share (mrq) | 0.36 USD |
Total Debt (mrq) | 129.83K USD |
Total Debt/Equity (mrq) | 1.44 USD |
Current Ratio (mrq) | 5.195 |
Book Value Per Share (mrq) | 0.449 |
Cash Flow Statement
Operating Cash Flow (ttm) | -12018274 USD |
Levered Free Cash Flow (ttm) | -6954863 USD |
Profile of Edesa Biotech
Country | United States |
State | ON |
City | Markham |
Address | 100 Spy Court |
ZIP | L3R 5H6 |
Phone | 289 800 9600 |
Website | https://www.edesabiotech.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 16 |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Q&A For Edesa Biotech Stock
What is a current EDSA stock price?
Edesa Biotech EDSA stock price today per share is 2.31 USD.
How to purchase Edesa Biotech stock?
You can buy EDSA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Edesa Biotech?
The stock symbol or ticker of Edesa Biotech is EDSA.
Which industry does the Edesa Biotech company belong to?
The Edesa Biotech industry is Biotechnology.
How many shares does Edesa Biotech have in circulation?
The max supply of Edesa Biotech shares is 6.99M.
What is Edesa Biotech Price to Earnings Ratio (PE Ratio)?
Edesa Biotech PE Ratio is now.
What was Edesa Biotech earnings per share over the trailing 12 months (TTM)?
Edesa Biotech EPS is -1.87 USD over the trailing 12 months.
Which sector does the Edesa Biotech company belong to?
The Edesa Biotech sector is Healthcare.
Edesa Biotech EDSA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}